32 completed, 7 recruiting, 4 unknown, 3 not yet recruiting. 50 Phase 1, 11 Phase 2.
Follow Placebo Control: new trials by email Literature Review of Placebo Control trials Research Report on Placebo Control
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain Green Tea Leaf Extract Decaffeinated, Placebo Control - Neuropathic Pain, Cancer Treatment | Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 20 | 2026-09-30 | 2026-08-21 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS HT31-1, Saline (0.9%, sterile, for infusion) - ARDS (Acute Respiratory Distress Syndrome) | Phase 1 | Recruiting | HTIC, Inc | 24 | 2026-05-28 | 2026-09-16 |
| A Study of JPH034 in Healthy Adult Participants JPH034, Placebo Control - Health Adult Subjects | Phase 1 | Recruiting | J-Pharma Co., Ltd. | 40 | 2026-03-22 | 2026-08-06 |
| Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers RN5681, Placebo control - High Cholesterol | Phase 1 | Recruiting | Ikaria Bioscience Pty Ltd | 60 | 2026-03-12 | 2026-04-03 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants HY6725, Placebo Control - Healthy | Phase 1 | Recruiting | Newsoara Biopharma Co., Ltd. | 74 | 2026-02-06 | 2026-03-11 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants HY8931, Placebo Control - Healthy | Phase 1 | Recruiting | Newsoara Biopharma Co., Ltd. | 60 | 2026-01-14 | 2026-03-11 |
| A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults QLS7305 Injection, Placebo Control - Healthy Volunteers - Male and Female | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-01-01 | 2025-12-31 |
| A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea. Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% - Rosacea | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 865 | 2025-12-09 | 2026-08-31 |
| Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity RN3161, Placebo Control, Tirzepatide - Obesity &Amp; Overweight | Phase 1 / Phase 2 | Recruiting | Ikaria Bioscience Pty Ltd | 104 | 2025-11-04 | 2025-11-24 |
| hUC-MSC-Exo Therapy for Autoimmune Encephalitis Human umbilical cord mesenchymal stem cell derived exosomes, Placebo Control - Autoimmune Encephalitis | Phase 1 / Phase 2 | Not yet recruiting | Xuanwu Hospital, Beijing | 38 | 2025-11-01 | 2025-08-20 |
| A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 575 | 2025-10-13 | 2026-04-22 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| Diclofenac Dose Response Study Diclofenac 100mg, Diclofenac 75mg, Diclofenac 50mg - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Completed | University of Maryland, Baltimore | 23 | 2024-12-01 | 2026-09-08 |
| Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents Recombinant COVID-19 vaccine (Sf9 cells), Placebo control - COVID-19 | Phase 1 / Phase 2 | Withdrawn | WestVac Biopharma Co., Ltd. | 2024-07-01 | 2025-03-28 | |
| A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 382 | 2024-05-13 | 2024-11-05 |
| Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System [11C]-PHNO, Calcitriol, Placebo Control - Opioid Use Disorder | Phase 1 | Completed | Yale University | 5 | 2024-03-13 | 2025-11-14 |
| Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults FC-12738, Saline - Safety Issues, Tolerance | Phase 1 | Completed | Neurodegenerative Disease Research Inc | 24 | 2024-02-20 | 2025-05-25 |
| Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose), Placebo control - Healthy Volunteers | Phase 1 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 300 | 2023-07-22 | 2024-04-03 |
| A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects Epetraborole and matching placebo, Epetraborole, Placebo - Healthy Volunteers | Phase 1 | Completed | AN2 Therapeutics, Inc | 24 | 2023-06-05 | 2023-12-21 |
Showing 20 of 50. Sign in to see all of them.
Influenza, Human (3) · Acne Vulgaris (2) · COVID-19 (2) · Fecal Incontinence (2) · Obesity (2) · Abruptio Placentae (1) · Acute Lung Injury (1) · Alcohol-Related Disorders (1) · Alcoholism (1) · Amyotrophic Lateral Sclerosis (1) · Autoimmune Diseases of the Nervous System (1) · Autonomic Nervous System Diseases (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · Chemically-Induced Disorders (1)
Sun Pharmaceutical Industries, Inc. (4) · Vaxart (4) · Ikaria Bioscience Pty Ltd (2) · Newsoara Biopharma Co., Ltd. (2) · Norgine (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · University of Maryland, Baltimore (2) · AN2 Therapeutics, Inc (1) · Baxalta now part of Shire (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · British University In Egypt (1) · Everfront Biotech Co., Ltd. (1) · Gan and Lee Pharmaceuticals, USA (1) · HTIC, Inc (1) · Inotek Pharmaceuticals Corporation (1)
United States (26) · Australia (5) · China (3) · United Kingdom (3) · Belgium (2) · Germany (2) · India (2) · Bulgaria (1) · Israel (1) · Kenya (1) · Malaysia (1) · Rwanda (1) · South Africa (1) · Taiwan (1)
Natalie Yantovskiy (4) · Weifen Zhou, Dr. (2) · Amani Elbarazi, Ph.D. (1) · Apinya Vutikullird, DO (1) · Ashok Seth, FRCP, FACC (1) · Christine L Lau, MD, MBA (1) · David Liebowitz, MD, PhD (1) · Elisabeth Kruse, PhD (1) · Etienne Karita, MD, M.Sc., MSPH (1) · Fengcai Zhu (1) · Gaudensia Mutua, MB ChB, MPH (1) · Glenda Gray, MBBCH, FCPaeds(SA) (1) · Haichang Wang, MD,PHD (1)
PMID 18598362, PMID 20576835, PMID 21127322, PMID 21285968, PMID 23357198, PMID 24379032, PMID 26333337, PMID 26833336, PMID 29997294, PMID 32790066
2015 (1), 2017 (1), R01DA019992 (1)